Drug targeting to choroidal neovascularization

Area of Science:

• Ophthalmology
• Biomedical Engineering
• Pharmacology

Background:

• Subfoveal choroidal neovascularization (CNV) is a primary cause of vision loss in age-related macular degeneration (AMD).
• Current anti-angiogenic treatments for CNV administered systemically can cause side effects and require frequent dosing.
• The unique vascular characteristics of CNV, similar to tumor vasculature, suggest potential for targeted drug delivery.

Purpose of the Study:

• To review current strategies for developing targeted drug delivery systems for subfoveal choroidal neovascularization (CNV).
• To explore the feasibility of targeting CNV using principles similar to tumor targeting.

Main Methods:

• Review of existing literature on drug delivery systems for CNV.
• Analysis of the anatomical and physiological similarities between CNV vasculature and tumor vasculature.
• Description of passive and active targeting approaches for CNV drug delivery.

Main Results:

• Drug targeting to CNV is feasible due to its enhanced permeability and retention (EPR) effect, analogous to tumor targeting.
• Passive targeting leverages the EPR effect for drug accumulation in CNV tissues.
• Active targeting utilizes specific ligands to bind to receptors on CNV endothelial cells.

Conclusions:

• Targeted drug delivery systems offer a promising approach to improve the safety and efficacy of CNV treatments.
• Both passive and active targeting strategies can be employed to deliver therapeutic agents directly to CNV lesions.
• Further development of these systems could significantly benefit patients with AMD and associated CNV.